Feb 13, 2021 / 10:30PM GMT
Operator
Thank you for joining us, ladies and gentlemen. Please welcome Susan Hubbard.
Susan T. Hubbard - Exelixis, Inc. - EVP of Public Affairs & IR
Hello, everyone, and welcome to the Exelixis Investor Briefing at the ASCO GU 2021 Virtual Conference. I'm Susan Hubbard, Executive Vice President of Public Affairs and Investor Relations at Exelixis.
We are pleased to have you join us following the close of a very busy ASCO GU 2021 and week in general for Exelixis. We have a very prestigious panel of physicians joining us today for a review of the array of cabozantinib data presented at the conference and to discuss the evolving renal cell carcinoma landscape. Following our panel discussion, we'll have a question-and-answer session where we'll field questions from the audience.
Before I turn the session over to Mark -- to Mike, sorry, Mike, I will remind you that during the course of this presentation, we will be making forward-looking statements regarding future events or the future performance of the company, including statements related to the
Exelixis Inc Investor Briefing to Discuss Data Presented at ASCO GU 2021 Transcript
Feb 14, 2021
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers